Many drug candidates fail in clinical development due to their insufficient selectivity that may cause undesired side effects. Therefore, modern drug discovery is routinely supported by computational techniques, which can identify alternate molecular targets with a significant potential for cross-reactivity. In particular, the development of highly selective kinase inhibitors is complicated by the strong conservation of the ATP-binding site across the kinase family. In this paper, we describe X-ReactKIN, a new machine learning approach that extends the modeling and virtual screening of individual protein kinases to a system level in order to construct a cross-reactivity virtual profile for the human kinome. To maximize the coverage of the k...
Designing kinase inhibitors is always an area of interest because kinases are involved in many disea...
Drug discovery programs frequently target members of the human kinome and try to identify small mole...
Motivation and method: Small-molecule inhibitors targeting the ATP binding pocket of the catalytic d...
Kinase-targeted drug design is challenging. It requires designing inhibitors that can bind to specif...
Owing to the intrinsic polypharmacological nature of most small-molecule kinase inhibitors, there is...
The protein kinases are a large family of enzymes that play fundamental roles in propagating signals...
The growing interest in the identification of kinase inhibitors, promising therapeutics in the treat...
Despite decades of intensive search for compounds that modulate the activity of particular protein t...
Reliable in silico prediction methods promise many advantages over experimental high-throughput scre...
Rational design of kinase inhibitors remains a challenge partly because there is no clear delineatio...
ABSTRACT: Large corpora of kinase small molecule inhibitor data are accessible to public sector rese...
The discovery of selective inhibitors of biological target proteins is the primary goal of many drug...
Motivation and method: Small-molecule inhibitors targeting the adenosine triphosphate (ATP) binding ...
Background: The human kinome contains many important drug targets. It is well-known that inhibitors...
Protein kinases remain among the most versatile and prospective therapeutic drug targets with curren...
Designing kinase inhibitors is always an area of interest because kinases are involved in many disea...
Drug discovery programs frequently target members of the human kinome and try to identify small mole...
Motivation and method: Small-molecule inhibitors targeting the ATP binding pocket of the catalytic d...
Kinase-targeted drug design is challenging. It requires designing inhibitors that can bind to specif...
Owing to the intrinsic polypharmacological nature of most small-molecule kinase inhibitors, there is...
The protein kinases are a large family of enzymes that play fundamental roles in propagating signals...
The growing interest in the identification of kinase inhibitors, promising therapeutics in the treat...
Despite decades of intensive search for compounds that modulate the activity of particular protein t...
Reliable in silico prediction methods promise many advantages over experimental high-throughput scre...
Rational design of kinase inhibitors remains a challenge partly because there is no clear delineatio...
ABSTRACT: Large corpora of kinase small molecule inhibitor data are accessible to public sector rese...
The discovery of selective inhibitors of biological target proteins is the primary goal of many drug...
Motivation and method: Small-molecule inhibitors targeting the adenosine triphosphate (ATP) binding ...
Background: The human kinome contains many important drug targets. It is well-known that inhibitors...
Protein kinases remain among the most versatile and prospective therapeutic drug targets with curren...
Designing kinase inhibitors is always an area of interest because kinases are involved in many disea...
Drug discovery programs frequently target members of the human kinome and try to identify small mole...
Motivation and method: Small-molecule inhibitors targeting the ATP binding pocket of the catalytic d...